We are live on ! Find out more
PAI

Palo Alto Investors Portfolio holdings

AUM $654M
1-Year Est. Return 77.8%
This Fund
S&P 500
This Quarter Est. Return
+10.98%
1 Year Est. Return
+77.8%
3 Year Est. Return
+127.05%
5 Year Est. Return
+199.24%
10 Year Est. Return
+2,229.57%
AUM
$1.21B
AUM Growth
+$34.2M
Cap. Flow
+$11.4M
Cap. Flow %
0.94%
Top 10 Hldgs %
87.78%
Holding
31
New
2
Increased
12
Reduced
3
Closed
1

Top Buys

Rank Stock Value
1
STAA icon
STAAR Surgical
STAA
+$7M
2
GOSS icon
Gossamer Bio
GOSS
+$6.56M
3
NVCR icon
NovoCure
NVCR
+$2.62M
4
RLMD icon
Relmada Therapeutics
RLMD
+$1.87M
5
EHTH icon
eHealth
EHTH
+$1.61M

Top Sells

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.68M
2
VNDA icon
Vanda Pharmaceuticals
VNDA
+$4.25M
3
ALIM
Alimera Sciences
ALIM
+$544K
4
RVNC
Revance Therapeutics, Inc.
RVNC
+$418K

Sector Composition

Rank Sector Weight
1 Healthcare 97.91%
2 Financials 2.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BMRN icon
1
BioMarin Pharmaceuticals
BMRN
$13.5B
$178M 14.75%
1,831,035
-54,776
-3% -$5.68M
RVNC
2
DELISTED
Revance Therapeutics, Inc.
RVNC
$170M 14.06%
5,270,209
-13,400
-0.3% -$418K
UTHR icon
3
United Therapeutics
UTHR
$22.1B
$141M 11.64%
627,514
+2,100
+0.3% +$518K
FOLD
4
DELISTED
Amicus Therapeutics
FOLD
$117M 9.67%
10,524,022
+30,300
+0.3% +$373K
BIIB icon
5
Biogen
BIIB
$30.1B
$106M 8.78%
381,282
+1,200
+0.3% +$332K
INSM icon
6
Insmed
INSM
$29B
$100M 8.32%
5,889,491
+18,200
+0.3% +$354K
STAA icon
7
STAAR Surgical
STAA
$1.24B
$86.2M 7.14%
1,347,322
+107,245
+9% +$7M
PRTA icon
8
Prothena Corp
PRTA
$473M
$80.6M 6.68%
1,663,777
+5,200
+0.3% +$275K
ACAD icon
9
Acadia Pharmaceuticals
ACAD
$5.07B
$45.3M 3.75%
2,405,793
+29,424
+1% +$560K
SAGE
10
DELISTED
Sage Therapeutics
SAGE
$36.1M 2.99%
859,517
+3,000
+0.4% +$129K
EHTH icon
11
eHealth
EHTH
$39.1M
$25.2M 2.09%
2,689,379
+204,900
+8% +$1.61M
ALGN icon
12
Align Technology
ALGN
$12.3B
$24.9M 2.07%
74,605
– –
KPTI icon
13
Karyopharm Therapeutics
KPTI
$47.6M
$22.1M 1.83%
378,392
+1,347
+0.4% +$66.5K
ALKS icon
14
Alkermes
ALKS
$8.26B
$17M 1.41%
603,400
– –
SNDX icon
15
Syndax Pharmaceuticals
SNDX
$1.81B
$12.9M 1.07%
612,600
– –
PRVB
16
DELISTED
Provention Bio, Inc. Common Stock
PRVB
$9.42M 0.78%
390,800
– –
ANAB icon
17
AnaptysBio
ANAB
$1.71B
$9.38M 0.78%
431,224
+200
+0% +$4.86K
GOSS icon
18
Gossamer Bio
GOSS
$88.9M
$4.37M 0.36%
3,465,152
+3,427,402
+9,079% +$6.56M
CYTK icon
19
Cytokinetics
CYTK
$10.6B
$3.93M 0.33%
111,717
– –
TVTX icon
20
Travere Therapeutics
TVTX
$5.68B
$3.73M 0.31%
166,069
– –
VNDA icon
21
Vanda Pharmaceuticals
VNDA
$298M
$3.28M 0.27%
482,697
-604,910
-56% -$4.25M
KZR
22
DELISTED
Kezar Life Sciences
KZR
$2.05M 0.17%
65,620
– –
NVCR icon
23
NovoCure
NVCR
$2.06B
$1.97M 0.16%
+32,790
New +$2.62M
GRTS
24
DELISTED
Gritstone bio, Inc. Common Stock
GRTS
$1.85M 0.15%
666,127
– –
ALDX icon
25
Aldeyra Therapeutics
ALDX
$91.1M
$1.6M 0.13%
160,800
– –
1
2

Similar funds

RRA
Round Rock Advisors Wilton, Connecticut $654M AUM 22.95% 1-Year Est. Return
AG
Alibaba Group Causeway Bay, Hong Kong $653M AUM 16.11% 1-Year Est. Return
BL
BWCP LP Dallas, Texas $656M AUM 41.58% 1-Year Est. Return
CG
CFO4Life Group Coppell, Texas $656M AUM 17.88% 1-Year Est. Return
GAMA
Graticule Asia Macro Advisors New York $649M AUM
PIM
Parker Investment Management Menlo Park, California $659M AUM 52.52% 1-Year Est. Return
ACA
Apis Capital Advisors New York $648M AUM 302.67% 1-Year Est. Return
RK
Rather & Kittrell Knoxville, Tennessee $648M AUM 14.68% 1-Year Est. Return

Palo Alto Investors's Q1 2023 Portfolio in Review

As of Q1 2023, Palo Alto Investors held 31 positions worth $1.21B, up 2.9% from $1.17B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Palo Alto Investors's Q1 2023 filing shows 2 new, 12 increased, 3 reduced and 1 closed positions. Its largest new stake was NovoCure: 32,790 shares worth $1.97M. The largest sale was BioMarin Pharmaceuticals, an estimated $5.68M.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier, followed by Financials.

  • Palo Alto Investors's largest Q1 2023 buy was NovoCure: 32,790 shares worth $1.97M.
  • Palo Alto Investors added most to STAAR Surgical in Q1 2023, an estimated $7M increase.
  • Palo Alto Investors's biggest Q1 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $5.68M.
  • Palo Alto Investors fully exited Alimera Sciences in Q1 2023, selling an estimated $544K.
  • Palo Alto Investors's ten largest holdings make up 88% of its $1.21B portfolio in Q1 2023.
  • Palo Alto Investors opened 2 new positions and closed 1 in Q1 2023.
  • Palo Alto Investors's portfolio value rose 2.9% quarter-over-quarter to $1.21B.

Based on Palo Alto Investors's 13F filing for Q1 2023, filed 15 May 2023.